Sara K Vesely

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8831456/publications.pdf

Version: 2024-02-01

192 11,533 55 102 papers citations h-index g-index

192 192 192 192 7853

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	New methods facilitated the process of prioritizing questions and health outcomes in guideline development. Journal of Clinical Epidemiology, 2022, 143, 91-104.	5.0	5
2	Abstract P3-19-20: Are traditional indications for radiation therapy appropriate for small cell carcinoma of the breast: An NCDB outcomes analysis and treatment utilization report. Cancer Research, 2022, 82, P3-19-20-P3-19-20.	0.9	0
3	Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood, 2022, 140, 785-789.	1.4	4
4	The impact of BMI on the response to immunotherapy in lung cancer Journal of Clinical Oncology, 2022, 40, e21003-e21003.	1.6	1
5	A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium Journal of Clinical Oncology, 2021, 39, 5527-5527.	1.6	1
6	Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. Blood Advances, 2021, 5, 2919-2924.	5.2	0
7	GRADE notes: How to use GRADE when there is "no―evidence? A case study of the expert evidence approach. Journal of Clinical Epidemiology, 2021, 137, 231-235.	5. O	21
8	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Advances, 2021, 5, 4721-4726.	5.2	10
9	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. Journal of Clinical Epidemiology, 2021, 138, 115-127.	5. O	4
10	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. Blood, 2021, 138, 3039-3039.	1.4	0
11	Prospective Associations Among Youth Religiosity and Religious Denomination and Youth Contraception Use. Journal of Religion and Health, 2020, 59, 555-569.	1.7	3
12	Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist, 2020, 25, e276-e283.	3.7	55
13	Laboratory monitoring during pregnancy and postâ€partum hemorrhage in women with von Willebrand disease. Journal of Thrombosis and Haemostasis, 2020, 18, 604-608.	3.8	8
14	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2496-2502.	3.8	188
15	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	3.8	142
16	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2503-2512.	3.8	25
17	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. Melanoma Management, 2020, 7, MMT43.	0.5	7
18	Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Science OA, 2020, 6, FSO581.	1.9	11

#	Article	IF	CITATIONS
19	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Advances, 2020, 4, 2351-2365.	5.2	26
20	Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. Anticancer Research, 2020, 40, 847-855.	1.1	9
21	Impact of gender and caregiving responsibilities on academic success in hematology. Blood Advances, 2020, 4, 755-761.	5.2	6
22	PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2020, 38, e21655-e21655.	1.6	0
23	An Open-Label, Single-Arm, Efficacy Study of Tranexamic Acid in Adolescents with Heavy Menstrual Bleeding. Journal of Pediatric and Adolescent Gynecology, 2019, 32, 305-311.	0.7	16
24	Von Willebrand disease screening in women undergoing hysterectomy for heavy menstrual bleeding. Haemophilia, 2019, 25, e188-e191.	2.1	4
25	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115.	3.5	99
26	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	5.2	684
27	Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 138-142.	1.3	5
28	Tobacco Use in Adults With Mental Illness: An Overview of One State-Wide Tobacco Cessation Program. Journal of Smoking Cessation, 2019, 14, 132-137.	1.0	0
29	Clinical characteristics and predictors of outcomes in patients with fibrolamellar carcinoma: An eleven-year analysis of the National Cancer Database (NCDB) Journal of Clinical Oncology, 2019, 37, 413-413.	1.6	0
30	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist–oncologists. Journal of Thrombosis and Thrombolysis, 2018, 46, 24-30.	2.1	11
31	Mobile Application vs Paper Pictorial Blood Assessment Chart to Track Menses in Young Women: A Randomized Cross-over Design. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 84-88.	0.7	29
32	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatric Blood and Cancer, 2018, 65, e26736.	1.5	51
33	Sexual Knowledge, Attitudes, and Behaviors of Youth Living in Group Homes. Health Behavior and Policy Review, 2018, 5, 74-87.	0.4	4
34	American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Advances, 2018, 2, 3292-3316.	5 . 2	273
35	Can DNA methylation patterns be used as predictive biomarkers for chemotherapy response in osteosarcoma?. Journal of Clinical Oncology, 2018, 36, 11525-11525.	1.6	0
36	Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care, 2017, 40, 233-238.	8.6	36

#	Article	IF	Citations
37	Beyond the Effects of Comprehensive Sexuality Education: The Significant Prospective Effects of Youth Assets on Contraceptive Behaviors. Journal of Adolescent Health, 2017, 61, 678-684.	2.5	5
38	Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%â€20%. American Journal of Hematology, 2017, 92, E644-E646.	4.1	20
39	Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion, 2017, 57, 2532-2538.	1.6	18
40	Response to Comment on O'Brien et al. Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care 2017;40:233–238. Diabetes Care, 2017, 40, e62-e62.	8.6	1
41	Quinine-Induced Thrombotic Microangiopathy: A Report ofÂ19ÂPatients. American Journal of Kidney Diseases, 2017, 70, 686-695.	1.9	30
42	Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. Kidney International Reports, 2017, 2, 1088-1095.	0.8	9
43	Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances, 2017, 1, 590-600.	5. 2	207
44	Demographic Factors Predict Disparities in Number of Assets Youth Possess. American Journal of Health Behavior, 2017, 41, 652-660.	1.4	2
45	Outcomes and Prognostic Factors of Resected Salivary Gland Malignancies: Examining a Single Institution's 12-year Experience. Anticancer Research, 2017, 37, 5019-5025.	1.1	8
46	Von Willebrand Disease Screening in Women Undergoing Hysterectomy for Heavy Menstrual Bleeding. Blood, 2017, 130, 674-674.	1.4	2
47	The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis. Blood Coagulation and Fibrinolysis, 2016, 27, 648-652.	1.0	49
48	Towards automatic 3D bone marrow segmentation. , 2016, , .		2
49	Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood, 2016, 128, 2175-2178.	1.4	68
50	An automatic 3D CT/PET segmentation framework for bone marrow proliferation assessment. , 2016, 2016, 4126-4130.		3
51	Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127, 3092-3094.	1.4	99
52	Depression in adult patients with primary immune thrombocytopenia. American Journal of Hematology, 2016, 91, E462-3.	4.1	8
53	The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology. Blood, 2016, 128, 2881-2885.	1.4	5
54	Longâ€term outcomes of healthâ€related quality of life following diverse thrombotic microangiopathy syndromes. American Journal of Hematology, 2016, 91, E278-9.	4.1	1

#	Article	IF	Citations
55	The Predictive Influence of Youth Assets on Drinking and Driving Behaviors in Adolescence and Young Adulthood. Journal of Primary Prevention, 2016, 37, 231-245.	1.6	9
56	Diversity and severity of adverse reactions to quinine: A systematic review. American Journal of Hematology, 2016, 91, 461-466.	4.1	43
57	Prognostic significance of weight loss and nutritional markers during induction chemotherapy of newly diagnosed acute myeloid leukemia (AML) patients Journal of Clinical Oncology, 2016, 34, e21591-e21591.	1.6	0
58	Poorly differentiated malignant salivary gland tumors (MSGTs) amenable to resection and their association with higher stage, higher prevalence in males, and poor prognosis Journal of Clinical Oncology, 2016, 34, e17563-e17563.	1.6	0
59	Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, 709-714.	4.1	59
60	The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood, 2015, 125, 1526-1531.	1.4	102
61	Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125, 616-618.	1.4	282
62	Prospective Associations Among Assets and Successful Transition to Early Adulthood. American Journal of Public Health, 2015, 105, e51-e56.	2.7	12
63	Prospective Association Between Negative Life Events and Initiation of Sexual Intercourse: The Influence of Family Structure and Family Income. American Journal of Public Health, 2015, 105, 598-604.	2.7	7
64	The Prospective Association of Youth Assets With Tobacco Use in Young Adulthood. American Journal of Health Education, 2015, 46, 329-337.	0.6	2
65	<scp>D</scp> rugâ€induced thrombotic microangiopathy: <scp>E</scp> xperience of the <scp>O</scp> klahoma registry and the BloodCenter of <scp>W</scp> isconsin. American Journal of Hematology, 2015, 90, 406-410.	4.1	95
66	Prospective Associations Among Youth Assets in Young Adults and Tobacco Use. American Journal of Preventive Medicine, 2015, 48, S94-S101.	3.0	20
67	Central nervous system metastasis in gynecologic cancer: Symptom management, prognosis and palliative management strategies. Gynecologic Oncology, 2015, 136, 472-477.	1.4	15
68	Patterns of Care for Localized Breast Cancer in Oklahoma, 2003–2006. Women and Health, 2015, 55, 975-995.	1.0	6
69	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	2.5	4
70	Prospective Associations between Negative Life Events and Youth Tobacco Use. American Journal of Health Behavior, 2014, 38, 942-950.	1.4	5
71	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. American Journal of the Medical Sciences, 2014, 347, 190-194.	1.1	13
72	The Predictive Influence of Family and Neighborhood Assets on Fighting and Weapon Carrying from Mid- to Late Adolescence. Prevention Science, 2014, 15, 473-484.	2.6	26

#	Article	IF	Citations
73	Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood, 2014, 123, 1674-1680.	1.4	61
74	A multiple motive/multi-dimensional approach to measure smokeless tobacco dependence. Addictive Behaviors, 2014, 39, 622-629.	3.0	10
75	Conflicts of Interest and Clinical Recommendations. American Journal of Medical Quality, 2014, 29, 53-60.	0.5	26
76	Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. European Journal of Haematology, 2014, 92, 156-163.	2.2	18
77	The influence of assets and environmental factors on gender differences in adolescent drug use. Journal of Adolescence, 2014, 37, 827-837.	2.4	9
78	Increased Urinary Albumin Excretion Following Recovery From Thrombotic Thrombocytopenic Purpura Due to Acquired ADAMTS13 Deficiency. American Journal of Kidney Diseases, 2014, 64, 317-318.	1.9	14
79	Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion, 2014, 54, 3257-3259.	1.6	16
80	Thrombotic Thrombocytopenic Purpura (TTP) Patient Attitudes Regarding Depression Management: a Qualitative Study. Blood, 2014, 124, 203-203.	1.4	1
81	Drug-induced thrombocytopenia in children. Pediatric Blood and Cancer, 2013, 60, 1975-1981.	1.5	21
82	Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Is risk stratification useful?. Gynecologic Oncology, 2013, 130, 411-415.	1.4	5
83	A Longitudinal Study of Youth Assets, Neighborhood Conditions, and Youth Sexual Behaviors. Journal of Adolescent Health, 2013, 52, 779-785.	2.5	44
84	First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?. Transfusion, 2013, 53, 235-237.	1.6	24
85	Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682.	1.5	193
86	Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood, 2013, 121, 4457-4462.	1.4	87
87	Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, 2013, 122, 2023-2029.	1.4	161
88	Youth gender differences in alcohol use: A prospective study of multiple youth assets and the neighborhood environment. Open Journal of Preventive Medicine, 2013, 03, 219-228.	0.3	6
89	Determinants of Salivary Cotinine Concentrations Among Smokeless Tobacco Users. Nicotine and Tobacco Research, 2012, 14, 1229-1234.	2.6	15
90	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	3.5	69

#	Article	IF	Citations
91	Antithrombotic Therapy in Neonates and Children. Chest, 2012, 141, e737S-e801S.	0.8	1,229
92	Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Medicale, 2012, 41, e177-e188.	1.9	35
93	Determining a definite diagnosis of primary immune thrombocytopenia by medical record review. American Journal of Hematology, 2012, 87, 843-847.	4.1	11
94	Prevalence of primary immune thrombocytopenia in Oklahoma. American Journal of Hematology, 2012, 87, 848-852.	4.1	75
95	Schoolâ€Related Assets and Youth Risk Behaviors: Alcohol Consumption and Sexual Activity. Journal of School Health, 2012, 82, 3-10.	1.6	37
96	A seasonal association of incident cases of thrombotic thrombocytopenic purpura was not observed in the Oklahoma TTPâ€HUS Registry. Transfusion, 2012, 52, 1593-1594.	1.6	7
97	Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpuraâ€hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion, 2012, 52, 2525-2532.	1.6	63
98	Parental Youth Assets and Sexual Activity: Differences by Race/Ethnicity. American Journal of Health Behavior, 2011, 35, 513-24.	1.4	10
99	Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion, 2011, 51, 2237-2243.	1.6	27
100	Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets. Transfusion, 2011, 51, 2690-2694.	1.6	10
101	Fatigue in adult patients with primary immune thrombocytopenia. European Journal of Haematology, 2011, 86, 420-429.	2.2	74
102	Systemic infections mimicking thrombotic thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 743-751.	4.1	87
103	Associations between Youth Assets and Sexual Intercourse by Household Income. American Journal of Health Promotion, 2011, 25, 301-309.	1.7	4
104	The association of attendance at religious services and involvement in church/religious activities and youth assets, by gender, with youth's engagement in sexual intercourse. Health Education, 2010, 110, 125-134.	0.9	3
105	Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood, 2010, 116, 2127-2133.	1.4	127
106	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	1.4	477
107	The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. American Journal of Hematology, 2010, 85, 174-180.	4.1	308
108	Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolyticâ€uremic syndromes. American Journal of Hematology, 2010, 85, 844-847.	4.1	75

#	Article	IF	Citations
109	Youth Assets and Sexual Risk Behavior: Differences Between Male and Female Adolescents. Health Education and Behavior, 2010, 37, 343-356.	2.5	33
110	Youth Assets and Delayed Coitarche Across Developmental Age Groups. Journal of Early Adolescence, 2010, 30, 277-304.	1.9	14
111	Reliability and Validity of the Youth Asset Survey: An Update. American Journal of Health Promotion, 2010, 25, e13-e24.	1.7	36
112	First Symptoms In Idiopathic Thrombotic Thrombocytopenic Purpura (TTP): What Are They and When Do They Occur? Blood, 2010, 116, 1427-1427.	1.4	2
113	Frequency and Significance of HIV Infection among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. Clinical Infectious Diseases, 2009, 48, 1129-1137.	5.8	48
114	Corticosteroid sideâ€effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. European Journal of Haematology, 2009, 83, 175-182.	2.2	64
115	Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient perspectives. European Journal of Haematology, 2009, 83, 497-498.	2.2	11
116	Adjuvant chemotherapy for the "oldest old―ovarian cancer patients. Cancer, 2009, 115, 1472-1480.	4.1	15
117	Longâ€ŧerm deficits in healthâ€related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 118-124.	1.6	61
118	Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion, 2009, 49, 392-394.	1.6	42
119	Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 873-887.	1.6	99
120	Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 1092-1101.	1.6	73
121	Drug-Induced Thrombocytopenia. Drug Safety, 2009, 32, 85-86.	3.2	20
122	Referral of patients with thrombocytopenia from primary care clinicians to hematologists. Blood, 2009, 113, 4126-4127.	1.4	8
123	Methodological Considerations in a Community-Based Longitudinal Study. American Journal of Health Behavior, 2009, 33, 58-68.	1.4	27
124	Twiceâ€daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion, 2008, 48, 349-357.	1.6	38
125	Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion, 2008, 48, 382-392.	1.6	76
126	Protective Assets for Non-use of Alcohol, Tobacco and Other Drugs among Urban American Indian Youth in Oklahoma. Maternal and Child Health Journal, 2008, 12, 82-90.	1.5	54

#	Article	IF	Citations
127	Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpuraâ€Hemolytic Uremic Syndrome Registry. Journal of Clinical Apheresis, 2008, 23, 129-137.	1.3	38
128	Support groups for patients who have recovered from thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2008, 23, 168-169.	1.3	12
129	Sporadic bloody diarrhoeaâ€associated thrombotic thrombocytopenic purpuraâ€haemolytic uraemic syndrome: an adult and paediatric comparison. British Journal of Haematology, 2008, 141, 696-707.	2.5	50
130	The Oklahoma Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 2008, 80, 277-286.	2.2	40
131	Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood, 2008, 112, 4003-4008.	1.4	171
132	The Prevalence of Immune Thrombocytopenic Purpura (ITP) Blood, 2008, 112, 1277-1277.	1.4	3
133	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases. Oncologist, 2007, 12, 11-19.	3.7	117
134	Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica, 2007, 92, 936-943.	3.5	75
135	Overlapping Features of Thrombotic Thrombocytopenic Purpura and Systemic Lupus Erythematosus. Southern Medical Journal, 2007, 100, 512-514.	0.7	40
136	Parental communication and youth sexual behaviour. Journal of Adolescence, 2007, 30, 449-466.	2.4	210
137	Drug-Induced Thrombocytopenia. Drug Safety, 2007, 30, 185-186.	3.2	12
138	Does Family Structure Matter in the Relationships Between Youth Assets and Youth Alcohol, Drug and Tobacco Use?. Journal of Research on Adolescence, 2007, 17, 743-766.	3.7	25
139	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP) Blood, 2007, 110, 1311-1311.	1.4	3
140	The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a community service. Journal - Oklahoma State Medical Association, 2007, 100, 273-8.	0.4	8
141	Sexuality Education Beliefs Among Sexually Experienced Youth. American Journal of Sexuality Education, 2006, 1, 3-23.	1.0	3
142	Youth Assets and Sexual Abstinence in Native American Youth. Journal of Health Care for the Poor and Underserved, 2006, 17, 775-788.	0.8	8
143	Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2006, 46, 154-156.	1.6	131
144	Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. Journal of Clinical Apheresis, 2006, 21, 49-56.	1.3	97

#	Article	IF	Citations
145	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP) Blood, 2006, 108, 1067-1067.	1.4	3
146	Long-Term Abnormalities of Patient-Reported Outcomes after Recovery from Thrombotic Thrombocytopenic Purpura (TTP) Using Health Related Quality-of-Life (QOL) Measurements Blood, 2006, 108, 458-458.	1.4	2
147	Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP) Blood, 2006, 108, 91-91.	1.4	4
148	Minor Surgical Procedures - Survey of Hematologists To Determine Preferences Regarding Management of Hemophilia Patients Blood, 2006, 108, 4067-4067.	1.4	0
149	Youth-parent communication and youth sexual behavior: implications for physicians. Family Medicine, 2006, 38, 500-4.	0.5	28
150	Drug-Induced Thrombocytopenia: An Updated Systematic Review. Annals of Internal Medicine, 2005, 142, 474.	3.9	13
151	Youth Assets, Aggression, and Delinquency Within the Context of Family Structure. American Journal of Health Behavior, 2005, 29, 557-568.	1.4	21
152	Is immune thrombocytopenic purpura less common among black Americans?. Blood, 2005, 105, 1368-1369.	1.4	13
153	Relationships Among Youth Assets and Neighborhood and Community Resources. Health Education and Behavior, 2005, 32, 380-397.	2.5	58
154	Ferriman Gallwey Self-Scoring I: Performance Assessment in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4112-4114.	3.6	92
155	Youth Assets and Sexual Risk Behavior: The Importance of Assets for Youth Residing in One-Parent Households. Perspectives on Sexual and Reproductive Health, 2005, 37, 25-31.	3.3	43
156	Youth Assets and Sexual Risk Behavior: The Importance of Assets for Youth Residing in One-Parent Households. Perspectives on Sexual and Reproductive Health, 2005, 37, 25-31.	3.3	3
157	Youth assets, aggression, and delinquency within the context of family structure. American Journal of Health Behavior, 2005, 29, 557-68.	1.4	8
158	Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion, 2004, 44, 146-150.	1.6	75
159	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion, 2004, 44, 294-304.	1.6	219
160	Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2004, 44, 1149-1158.	1.6	124
161	Adolescent Violence: The Protective Effects of Youth Assets. Journal of Counseling and Development, 2004, 82, 268-276.	2.4	81
162	How Can We Provide the Best Care for Our Patients With Immune Thrombocytopenic Purpura?. Mayo Clinic Proceedings, 2004, 79, 456-457.	3.0	9

#	Article	IF	Citations
163	The Oklahoma thrombotic thrombocytopenic Purpura-Hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Seminars in Hematology, 2004, 41, 60-67.	3.4	125
164	The Association between Multiple Youth Assets and Sexual Behavior. American Journal of Health Promotion, 2004, 19, 12-18.	1.7	47
165	The Potential Protective Effect of Youth Assets on Adolescent Alcohol and Drug Use. American Journal of Public Health, 2004, 94, 1425-1430.	2.7	118
166	Clinical Utility of D-dimer in Patients With Suspected Pulmonary Embolism and Nondiagnostic Lung Scans or Negative CT Findings. Chest, 2004, 125, 851-855.	0.8	37
167	Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 2004, 104, 2623-2634.	1.4	561
168	ADAMTS13 and TTP: the clot thickens. Blood, 2004, 103, 3997-3998.	1.4	12
169	Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy. Annals of Internal Medicine, 2004, 140, 112.	3.9	114
170	The potential protective effects of youth assets from adolescent sexual risk behaviors. Journal of Adolescent Health, 2004, 34, 356-365.	2.5	88
171	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities Blood, 2004, 104, 856-856.	1.4	2
172	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency Blood, 2004, 104, 857-857.	1.4	11
173	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes Blood, 2004, 104, 858-858.	1.4	3
174	A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): The six-year experience of the Oklahoma TTP-HUS Study Group. Journal of Clinical Apheresis, 2003, 18, 16-20.	1.3	28
175	Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care. American Journal of Hematology, 2003, 74, 161-169.	4.1	64
176	Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion, 2003, 43, 415-416.	1.6	69
177	Immune Thrombocytopenic Purpura â€" Let the Treatment Fit the Patient. New England Journal of Medicine, 2003, 349, 903-905.	27.0	17
178	Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001. Journal of Pediatric Hematology/Oncology, 2003, 25, 130-133.	0.6	52
179	ADAMTS13 activity in thrombotic thrombocytopenic purpuraâ€"hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 2003, 102, 60-68.	1.4	649
180	Quinine Allergy Causing Acute Severe Systemic Illness: Report of 4 Patients Manifesting Multiple Hematologic, Renal, and Hepatic Abnormalities. Baylor University Medical Center Proceedings, 2003, 16, 21-26.	0.5	16

#	Article	IF	CITATIONS
181	Thrombotic Thrombocytopenic Purpura: From the Bench to the Bedside, but Not Yet to the Community. Annals of Internal Medicine, 2003, 138, 152.	3.9	15
182	Reports of Drug-Induced Thrombocytopenia. Annals of Internal Medicine, 2003, 138, 239.	3.9	13
183	A youth development approach to profiling sexual abstinence. American Journal of Health Behavior, 2003, 27 Suppl 1, S80-93.	1.4	7
184	An Adolescent Age Group Approach to Examining Youth Risk Behaviors. American Journal of Health Promotion, 2002, 16, 167-176.	1.7	56
185	Adolescent Tobacco Use: The Protective Effects of Developmental Assets. American Journal of Health Promotion, 2002, 16, 198-205.	1.7	74
186	Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor–cleaving protease activity. Blood, 2002, 99, 437-442.	1.4	60
187	Reliability and validity of the youth asset survey (YAS). Journal of Adolescent Health, 2002, 31, 247-255.	2.5	98
188	Unintentional platelet removal by plasmapheresis. Journal of Clinical Apheresis, 2001, 16, 55-60.	1.3	27
189	Quinine-Associated Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome: Frequency, Clinical Features, and Long-Term Outcomes. Annals of Internal Medicine, 2001, 135, 1047.	3.9	139
190	Health risk aversion, health risk affinity, and socio-economic position in the USA: The demographics of multiple risk. Health, Risk and Society, 2000, 2, 295-314.	1.7	10
191	Self-Reported Diagnostic and Management Strategies in Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Practicing Pediatric Hematology/Oncology Specialists. The American Journal of Pediatric Hematology/oncology, 2000, 22, 55-61.	1.3	47
192	Immune Thrombocytopenic Purpura. , 0, , 206-214.		0